Ipilimumab review delayed but shows promise for melanoma

The Melanoma Menace may be facing a new weapon called Yervoy (ipilimumab)

Effective weapons available to treat melanoma have been scarce and challenged in their effectiveness against melanoma. On December 2, 2010 at the FDA White Oak Campus, Yervoy was scheduled for review by the Oncologic Drugs Advisory Committee. To start, the consideration for approval will be in advanced melanoma in people who have received prior therapy. The research is growing for combination therapy and I expect that this is where the drug will end up.

Interestingly (but not unusual), the comapny presented additional information (DATA) to the FDA, hence it looks like the committee review will be delayed.  Visit www.clinicaltrials.gov to learn more about the current combination regimens that are being researched. 

Contact Us
 

Our Location

Office Hours
Monday:9:00 AM - 5:00 PM
Tuesday:9:00 AM - 5:00 PM
Wednesday:9:00 AM - 5:00 PM
Thursday:9:00 AM - 5:00 PM
Friday:9:00 AM - 5:00 PM
Saturday:Closed
Sunday:Closed